A.   Dementia, Breast cancer, Cigarette smoking, Cardiovascular disease, Ovarian cancer

B.   Dementia, Breast cancer, Ovarian cancer, Cardiovascular disease, Serious cardiovascular events

C.   Dementia, Breast cancer, Cigarette smoking, Cardiovascular disease, Serious cardiovascular events

D.   Dementia, Ovarian cancer, Cigarette smoking, Cardiovascular disease, Serious cardiovascular events

A.   Current use of medications for depression

B.   Compliance with the fertility drugs

C.   Current smoking status

D.   Presence of abnormal uterine bleeding

A.   The fetal heart rate is stable.

B.   The contractions can be fatal to the patient.

C.   The patient’s blood pressure is stable.

D.   The patient is ready for delivery.

A.   Antidiuretic hormone

B.   Follicle-stimulating hormone (FSH)

C.   Luteinizing hormone (LH)

D.   Adrenocorticotropic hormone

A.   Day 3

B.   Day 7

C.   Day 14

D.   Day 21

A.   Methylergonovine

B.   Megestrol

C.   Clomiphene

D.   Raloxifene

A.   Methylergonovine

B.   Magnesium sulfate

C.   Oxytocin

D.   Terbutaline

A.   Megestrol

B.   Methylergonovine

C.   Medroxyprogesterone acetate

D.   Indomethacin

A.   Follicle-stimulating hormone (FSH)

B.   Luteotropic hormone

C.   Luteinizing hormone (LH)

D.   Interstitial cell-stimulating hormone

A.   Biphasic

B.   Extended-cycle

C.   Monophasic

D.   Triphasic

A.   Phase 4

B.   Phase 2

C.   Phase 3

D.   Phase 1

A.   Esterified estrogens

B.   Alendronate

C.   Medroxyprogesterone

D.   Megestrol

A.   Postpartum hemorrhage

B.   Accelerated labor

C.   Termination of pregnancy

D.   Premature labor

A.   Higher-pitched voice

B.   Weight loss

C.   Dry skin

D.   Nausea

A.   Weight gain

B.   Dysmenorrhea

C.   Thrombophlebitis

D.   Hypertension

A.   Antidiuretic hormone

B.   Follicle-stimulating hormone

C.   Adrenocorticotropic hormone

D.   Luteinizing hormone

A.   Elevated progesterone levels inhibiting the release of the luteinizing hormone

B.   Interference with the proliferation of the fertilized ovum

C.   Diminished endometrial tissue proliferation

D.   Inhibition of the release of gonadotropins

A.   "Endometrial cancer risk can be reduced by adding progestin."

B.   "The progestin in the regimen will help prevent ovarian cancer."

C.   "The progestin in the regimen will help prevent breast cancer."

D.   "Vaginal cancer is prevented by adding progestin to the regimen."

A.   Weight loss

B.   Deep vein thrombosis

C.   Uterine bleeding

D.   Dysmenorrhea

A.   Choriogonadotropin alfa

B.   Ethinyl estradiol

C.   Clomiphene

D.   Progesterone

A.   Dinoprostone

B.   Indomethacin

C.   Clomiphene

D.   Oxytocin

A.   Monitor the patient’s blood pressure frequently.

B.   Assess pulse oximetry continuously.

C.   Suggest the patient take aluminum hydroxide with the medication.

D.   Administer acetaminophen as needed.

A.   Hot flashes

B.   Brown discoloration of face

C.   Loss of hair

D.   Yellow undertone to the skin

A.   Megestrol

B.   Estropipate

C.   Medroxyprogesterone

D.   Estrone

A.   Clomiphene

B.   Prostaglandin E

C.   Terbutaline

D.   Oxytocin

A.   Unopposed estrogen increases the risk of endometrial cancer.

B.   Monotherapy with a progestin increases breast cancer risk.

C.   Estrogen monotherapy increases the risk of breast cancer.

D.   Estradiol with progestin increases the risk of endometrial cancer.

A.   Sedentary lifestyle

B.   Smoking heavily every day

C.   Increased body mass index (BMI)

D.   Consumption of saturated fats

A.   To terminate pregnancy

B.   To treat gestational hypertension

C.   To treat pelvic inflammatory disease

D.   To induce cervical ripening

A.   Hot flashes, Vertigo, Loss of appetite

B.   Hot flashes, Loss of appetite, Joint pain

C.   Chest pain, Hot flashes, Loss of appetite

D.   Vertigo, Joint pain, Chest pain

A.   "This medication will help relieve the bone pain I have from my osteoporosis."

B.   "I need to take this medication with food to prevent damage to my esophagus."

C.   "I will take the medication on an empty stomach and not lie down for 30 minutes."

D.   "I need to decrease my intake of dairy products to prevent hypercalcemia."

A.   Warfarin, Cholestyramine

B.   Multivitamin, Atenolol

C.   Levothyroxine, Multivitamin

D.   Atenolol, Levothyroxine

A.   Promotes bone absorption of calcium

B.   Contains estrogen, which stimulates bone reabsorption

C.   Inhibits osteoclast-mediated bone reabsorption

D.   Stimulates estrogen receptors on the bone to increase bone density

A.   Ferritin

B.   Amoxicillin

C.   Levothyroxine

D.   Metformin

A.   "I have seen a great improvement in my sexual desire."

B.   "I have not experienced any uterine bleeding."

C.   "I no longer experience hot flashes."

D.   "I am no longer experiencing painful intercourse."

A.   "Decreased Gn-RH suppresses the release of follicle-stimulating hormone."

B.   "Estrogen levels inhibit the release of follicle-stimulating hormone."

C.   "High progesterone levels inhibit the release of luteinizing hormone."

D.   "Surges of Gn-RH, follicle-stimulating hormone, and luteinizing hormone stimulate ovulation."

A.   "Report missed menstrual periods."

B.   "Have a yearly mammogram."

C.   "Perform weight-bearing exercise."

D.   "Have tests for serum cholesterol."

A.   "Replace the bisphosphonate with calcitonin."

B.   "Obtain a prescription for increasing the bisphosphonate dose."

C.   "Space the medications 1 to 2 hours apart."

D.   "Discontinue the calcium supplement."

A.   Breast cancer

B.   Allergy to salmon

C.   Joint pain

D.   Current smoker

A.   Male condom with spermicidal jelly

B.   Medroxyprogesterone

C.   Cervical cap with spermicidal jelly

D.   Norethindrone and ethinyl estradiol

A.   Hypertension

B.   Anticonvulsant therapy

C.   Diabetes

D.   Antibiotic therapy

A.   Terbutaline

B.   Bed rest and hydration

C.   Magnesium sulfate

D.   Ritodrine

A.   "The treatment should be started as soon as possible."

B.   "You may need to stop smoking during the therapy."

C.   "The treatment is likely to cause endometrial cancer."

D.   "The therapy may cause thromboembolic events."

A.   Inform the patient about the benefits and risks of the therapy.

B.   Ask the patient to include soy in her diet.

C.   Advise the patient to engage in quiet activities.

D.   Persuade the patient to start the therapy.

A.   Tamoxifen

B.   Denosumab

C.   Ibandronate

D.   Calcitonin

A.   Fetal movement, Uterine hyperactivity, Complete blood cell count

B.   Fetal heart rate, Fetal movement, The patient’s blood pressure and pulse

C.   The patient’s blood pressure and pulse, Complete blood cell count, Uterine hyperactivity

D.   Uterine hyperactivity, Fetal heart rate, Complete blood cell count

A.   Low fluid intake

B.   Cigarette use

C.   Current tricyclic antidepressant use

D.   Use of herbal supplements

A.   Radiographic confirmation of cephalopelvic disproportion

B.   Absence of cervical ripening at 42 weeks’ gestation

C.   Vaginal bleeding at 38 weeks’ gestation

D.   Ineffective contractions in a full-term pregnancy

A.   Temperature

B.   Blood pressure

C.   Blood glucose

D.   Uterine contractions

A.   Pelvic inflammatory disease

B.   Uterine atony

C.   Hypertension

D.   Nausea and vomiting

A.   Monitor the patient for blurred vision. Administer it before placenta delivery. Assess for pelvic inflammatory disease. Question the prescription if the patient has liver disease.

B.   Administer it before placenta delivery. Monitor blood pressure during administration. Assess for pelvic inflammatory disease. Question the prescription if the patient has liver disease.

C.   Monitor the patient for blurred vision. Monitor blood pressure during administration. Administer it before placenta delivery. Question the prescription if the patient has liver disease.

D.   Monitor the patient for blurred vision. Monitor blood pressure during administration. Assess for pelvic inflammatory disease. Question the prescription if the patient has liver disease.

A.   Instruct the patient to bear down and push.

B.   Immediately discontinue intravenous (IV) fluids.

C.   Place the patient on her left side.

D.   Administer phentolamine mesylate.

A.   Obtain a prescription for terbutaline.

B.   Request a prescription to give calcium gluconate.

C.   Obtain a prescription for indomethacin.

D.   Decrease the drug dose immediately.

A.   Atropine

B.   Protamine sulfate

C.   Epinephrine

D.   Calcium gluconate

A.   Methylergonovine

B.   Megestrol

C.   Alendronate

D.   Estradiol

A.   For at least 6 weeks, starting at the end of the antibiotic regimen

B.   Until three throat cultures have been negative for the pathogen

C.   For at least 1 month after starting the antibiotic

D.   During the entire period the patient is taking the antibiotic

A.   Hirsutism, Bradycardia, Increased diuresis

B.   Blurred vision, Bradycardia, Increased diuresis

C.   Hirsutism, Dizziness,, Increased diuresis

D.   Anxiety, Dizziness, Blurred vision

A.   Ovarian failure

B.   Pulmonary embolism

C.   Abnormal vaginal bleeding

D.   Renal failure

A.   Softened cervix

B.   Midline fundus

C.   Decreased pain

D.   Strong contractions